Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial

Received 8 November 2018; editorial decision 25 January 2019; accepted 5 April 2019; published online March 28, 2019. Correspondence: K. E. Dooley, Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Osler 527, Baltimore, MD, USA (kdooley1@jhmi.edu). Clinical Infectious Diseases 2019;XX(XX):1–8 © The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. DOI: 10.1093/cid/ciz256 Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial

[1]  G. Maartens,et al.  Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin. , 2019, International journal of antimicrobial agents.

[2]  A. Taburet,et al.  Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high human immunodeficiency virus and tuberculosis burden countries: A systematic review , 2018, British journal of clinical pharmacology.

[3]  Jingtao Gao,et al.  Guidelines for treatment of drug-susceptible tuberculosis and patient care-2017 update , 2018 .

[4]  A. Hill,et al.  Risks of cardiovascular or central nervous system adverse events and immune reconstitution inflammatory syndrome, for dolutegravir versus other antiretrovirals: meta-analysis of randomized trials , 2017, Current opinion in HIV and AIDS.

[5]  M. Cotton,et al.  Antiretroviral treatment in HIV-infected children who require a rifamycin-containing regimen for tuberculosis , 2017, Expert opinion on pharmacotherapy.

[6]  C. Kapelios,et al.  Integrase Strand Transfer Inhibitors and the Emergence of Immune Reconstitution Inflammatory Syndrome (IRIS). , 2017, Current HIV research.

[7]  S. Hader,et al.  Expansion of Viral Load Testing and the Potential Impact on HIV Drug Resistance. , 2017, The Journal of infectious diseases.

[8]  I. Mcnicholl,et al.  Drug Interactions with Cobicistat- or Ritonavir-Boosted Elvitegravir. , 2016, AIDS reviews.

[9]  C. Rouzioux,et al.  Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship , 2014, The Journal of antimicrobial chemotherapy.

[10]  C. Delaugerre,et al.  Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial. , 2014, The Lancet. Infectious diseases.

[11]  A. Kashuba,et al.  Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor Dolutegravir , 2013, Clinical Pharmacokinetics.

[12]  Ilesh Jani,et al.  Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial. , 2013, The Lancet. Infectious diseases.

[13]  Timothy H. Self,et al.  Update on rifampin, rifabutin, and rifapentine drug interactions , 2013, Current medical research and opinion.

[14]  G. Maartens,et al.  The Safety, Effectiveness and Concentrations of Adjusted Lopinavir/Ritonavir in HIV-Infected Adults on Rifampicin-Based Antitubercular Therapy , 2012, PloS one.

[15]  Benjamin Young,et al.  Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. , 2012, The Lancet. Infectious diseases.

[16]  Lerato Mohapi,et al.  Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. , 2011, The New England journal of medicine.

[17]  Anneke Grobler,et al.  Integration of antiretroviral therapy with tuberculosis treatment. , 2011, The New England journal of medicine.

[18]  S. Vong,et al.  Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. , 2011, The New England journal of medicine.

[19]  W. El-Sadr,et al.  Timing of initiation of antiretroviral drugs during tuberculosis therapy. , 2010, The New England journal of medicine.

[20]  K. Ruxrungtham,et al.  A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  K. Dooley,et al.  Drug interactions involving combination antiretroviral therapy and other anti-infective agents: repercussions for resource-limited countries. , 2008, The Journal of infectious diseases.

[22]  G. Maartens,et al.  Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. , 2007, The Journal of infectious diseases.

[23]  J. Rockstroh,et al.  CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions--review of the literature. , 2007, European journal of medical research.

[24]  W. Wehrli,et al.  Rifampin: mechanisms of action and resistance. , 1983, Reviews of infectious diseases.

[25]  D. Mitchison,et al.  Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis. , 1981, The American review of respiratory disease.